Carcinoma, Basal Cell Clinical Trial
Official title:
Imiquimod 5% Cream for the Treatment of Periocular Basal Cell Carcinoma
This study aimed to prove the efficacy and safety of the use of imiquimod 5% cream in the periorbital region.
This is a prospective study including patients presenting in aggregate primary lesions affected by nodular BCC of the eyelid (all subjects were submitted to incisional biopsy at 2 mm punch) at the commencement of this study. All were submitted to a local treatment with Imiquimod 5% cream (Aldara ®), once daily, 5 days per week for 8-16 weeks (average). All subjects were submitted to a new incisional biopsy at 2 mm punch, after 12 weeks of treatment, and all of them were monitored monthly up to now.If positive biopsy (residue tumor) cases will managed with surgery. ;
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00875381 -
Analysis of Melanocytes (Pigment Cells) in Sun-Exposed Skin
|
N/A | |
| Recruiting |
NCT04362722 -
Intratumoral Administration of Daromun in Non-melanoma Skin Cancer Patients
|
Phase 2 | |
| Completed |
NCT00218829 -
DMSO-PDT of BCC - A 6 Year Follow up
|
N/A | |
| Completed |
NCT02674009 -
Observational Study to Determine the Effectiveness and Safety of Vismodegib (Erivedge®) in Participants With Locally Advanced Basal Cell Carcinoma (laBCC)
|
||
| Recruiting |
NCT05970497 -
A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
|
Phase 1 | |
| Terminated |
NCT02956889 -
To Assess The Efficacy And Safety Of Vismodegib And Radiotherapy In Advanced Basal Cell Carcinoma
|
Phase 2 | |
| Completed |
NCT01204073 -
A Study of TAK-441 in Adult Patients With Advanced Nonhematologic Malignancies
|
Phase 1 | |
| Completed |
NCT02029352 -
Topical Green Tea Ointment in Treatment of Superficial Skin Cancer
|
Phase 2/Phase 3 | |
| Completed |
NCT03569345 -
Basal Cell Carcinomas Treated With Ablative Fractional Laser and Ingenol Mebutate
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05463757 -
Oral Hedgehog Inhibitors in the Treatment of Basal Cell Carcinoma in the Netherlands: a Prospective Registration Study
|
||
| Completed |
NCT00189280 -
Aldara for the Treatment of Large and/or Multiple sBCC
|
Phase 3 | |
| Completed |
NCT03541252 -
Topical Laser-assisted Combination Chemotherapy for Basal Cell Carcinoma- a Clinical Study
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05133427 -
HIFU for Treatment of Non-nodular and Recurrent BCC
|
N/A | |
| Active, not recruiting |
NCT02367547 -
Superficial Basal Cell Cancer's Photodynamic Therapy: Comparing Three Photosensitizers: HAL and BF-200 ALA Versus MAL
|
Phase 1/Phase 2 | |
| Completed |
NCT00007631 -
Determine the Efficacy of Topical Tretinoin Cream for the Prevention of Nonmelanoma Skin Cancer
|
Phase 3 | |
| Active, not recruiting |
NCT05138328 -
Laser Treatment of Basal Cell Carcinoma Under Imaging Guidance
|
N/A | |
| Completed |
NCT03132636 -
PD-1 in Patients With Advanced Basal Cell Carcinoma Who Experienced Progression of Disease on Hedgehog Pathway Inhibitor Therapy, or Were Intolerant of Prior Hedgehog Pathway Inhibitor Therapy
|
Phase 2 | |
| Completed |
NCT00847912 -
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
|
Phase 4 | |
| Enrolling by invitation |
NCT02666833 -
Optical Imaging for Preoperative Delineation of Nonmelanoma Skin Cancers
|
N/A | |
| Completed |
NCT01482104 -
New Versus Approved Methyl-aminolevulinate Photodynamic Therapy (MAL-PDT) Regime in Basal Cell Carcinoma (BCC)
|
N/A |